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Abstract
Background: Since 2000, reported syphilis cases increased ten-fold in Canada, particularly among men who have
sex with men (MSM) co-infected with HIV. We characterized temporal patterns of of syphilis testing in a large
cohort of HIV patients in Ontario, Canada.
Methods: We analyzed data from a multi-site cohort of people in HIV care from 2000 to 2009. Data were obtained
from medical charts, interviews and record linkage with the syphilis test database at the Public Health Ontario
Laboratories. We estimated the proportion that had syphilis testing at least once per year and the period and
annual prevalence of reactive tests.
Results: Among 4232 participants, the annual proportion tested rose from 2.7% (95%CI 1.9, 3.5) in 2000 to 54.6%
(95%CI 52.9, 56.3) in 2009. Testing was most common for participants who were men who have sex with men
(MSM), aged <30, recently diagnosed with HIV, were antiretroviral treatment naive, had routine HIV lab testing at
least twice in that year, or tested for syphilis in the preceding year. The proportion with at least one reactive test in
2000–09 was 21.0% (95%CI 19.4, 22.7) for MSM, 5.3% (95%CI 3.3, 7.4) for non-MSM males, and 2.6% (95%CI 1.2, 4.0)
for women. Among MSM, the annual prevalence of reactive syphilis tests with high RPR titre (≥1:16) peaked at 3.8%
in 2009.
Conclusions: The burden of syphilis co-infection rose considerably among HIV-positive MSM, such that by 2009, at
least 1 in 5 men had laboratory evidence of current or past infection. Interventions may be needed to boost
syphilis testing to achieve goals set by guidelines even in settings with universal health care.
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Background
After years of decline, syphilis has re-emerged as a serious
health burden among urban men who have sex with men
(MSM) in industrialized countries [1]. In Canada, notifi-
able cases of infectious syphilis rose from 0.6 per 100,000
in 2000 to 5.0 per 100,000 in 2009 [2] and outbreaks have
been identified in urban centres across the country
[1,3-5]. Most reported cases are among MSM, many of
whom are co-infected with HIV. In Ontario, most
reported syphilis cases have been in the two largest cities,
Toronto and Ottawa, with concurrent HIV infection
present in 45% of cases; HIV prevalence might be even
higher given that HIV status was unknown for men who
were not tested for HIV or tested anonymously (personal
communication, Michael Whelan, Public Health Ontario,
April 30, 2012). In contrast, HIV prevalence is 18% and
11% among MSM in Toronto and Ottawa, respectively
[6,7] suggesting that HIV-positive men are over-
represented in syphilis transmission networks. For men
co-infected with HIV, the response to syphilis treatment
can be suboptimal, [8] the development of neurosyphilis
may be accelerated, [9] treatment decisions are more com-
plex, and HIV infectiousness may be enhanced [10].
Prompt syphilis testing and treatment is important to pre-
vent potential clinical sequelae and also to limit ongoing
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syphilis and HIV transmission. However, to our know-
ledge, patterns of syphilis testing among people with HIV
have yet to be explored in Ontario.
North American guidelines for syphilis testing among HIV-
positive MSM are generally consistent in recommending
at least annual testing. Canadian guidelines recommend
that people diagnosed with HIV undergo further screening
for syphilis and other sexually transmitted infections
(STIs); that STI risk be discussed routinely with HIV pa-
tients at each visit; and that MSM with STI risk, regardless
of HIV status, undergo syphilis screening at least yearly
[1]. U.S. guidelines recommend that sexually active per-
sons with HIV have routine screening for curable STIs, in-
cluding syphilis, at least annually [11].
Our goal was to describe syphilis testing patterns
among HIV patients in care in Ontario, Canada, a set-
ting which has publicly-funded universal access to med-
ically necessary health-care services. Specific objectives
were to estimate the proportion undergoing syphilis test-
ing at least annually; to characterize persons who were
testing compared to those who were not; and to estimate
the prevalence of past or current syphilis.
Methods
We analyzed data from the Ontario HIV Treatment Net-
work Cohort Study (OCS). The study design has been
described previously [12]. Briefly, the source population
consists of people aged 16 and older diagnosed with
HIV infection and who receive medical care in Ontario
at hospital-based specialty HIV outpatient clinics and
family practice units and community-based primary care
physician practices. In the Ontario setting, most HIV
care is provided by a small number of specialized practi-
tioners who offer integrated, interprofessional HIV out-
patient care, as well as a a significant amount of primary
care (Jean Bacon, OHTN, personal communication,
January 28, 2013). The 12 participating clinics served
over three-quarters of HIV patients in the province [12].
Participation in the OCS was voluntary. All provided writ-
ten, informed consent. Clinical data obtained as part of par-
ticipants’ routine health care were abstracted from clinic
records. From 1995–2007, participants self-completed a
questionnaire at enrolment. Since 2008, they underwent an
annual interview. The study protocol, research instruments
and forms received ethical approval from the University of
Toronto Human Subjects Review Committee and from the
individual study sites.
Syphilis testing and diagnosis
We obtained syphilis testing data through record linkage
with the Public Health Ontario Laboratories (PHOL),
the sole provider of syphilis testing in Ontario. Serology
is the primary diagnostic methodology used for syphilis
testing. Prior to August 2005, the testing algorithm
consisted of the non-treponemal Rapid Plasma Reagin
(RPR) test as a screen, followed by confirmatory test
methodologies including the Treponema pallidum par-
ticle agglutination test (TPPA) and the fluorescent trepo-
nemal antibody absorbed (FTA-ABS) test. Subsequently,
the testing algorithm changed to screening with a trepo-
nemal test, the Abbott chemiluminescent immunoassay,
followed by confirmatory testing with the RPR, TPPA,
and FTA-ABS tests [13]. The latter algorithm has greater
sensitivity to detect early syphilis cases.
We classified the requesting institution for each syph-
ilis test as (1) the HIV clinic at which the patient was
participating in the OCS; (2) a designated sexual health
clinic administered by local public health units; or (3) all
other health care providers combined.
We classified syphilis test results as (1) reactive, de-
fined as a reactive trepomenal test, regardless of RPR
titre; (2) non-reactive; or (3) undetermined. Given this
laboratory-test-based definition, a case with any test re-
activity included recent incident cases and persons with
evidence of past, treated syphilis infection. Furthermore,
we distinguished reactive cases as “acute” or “non-
acute”, defining acute as having an RPR titre of 1:16 or
greater, suggestive of infectious syphilis. In general, in-
fectious syphilis is considered to be more likely when
RPR titres are 1:32 or greater [1]. However, we used a
more liberal cut-point for our definition of acute syph-
ilis, a titre of 1:16, because serologic responses may be
altered in HIV co-infected patients, and can include
false-negative or delayed seropositivity [11,14]. We
reviewed medical chart data from participating HIV
clinics for information on syphilis stage, where available,
for all participants who had at least one acute syphilis
test in 2000–09.
Analysis
We analyzed data available as of December 2010, at
which time 5,644 participants had enrolled. PHOL syph-
ilis test records were available for the 2000–09 period.
Therefore, we restricted the analysis to participants
under prospective follow-up during that time (952 ex-
cluded) and for whom there was successful record link-
age to the HIV viral load database at the PHOL,
suggesting that any syphilis testing done by any care pro-
vider in Ontario should have been observable (460 ex-
cluded). The final analytical sample size was 4,232
participants. We conducted all statistical analyses using
SAS version 9.3 (SAS Institute, Inc., Cary, North Carolina).
All p-values were two-sided and statistical significance was
determined using the traditional p-value of < 0.05.
We used descriptive statistics to characterize partici-
pants included in the analysis, the proportion that had at
least one linked syphilis test, and the type of requesting
institution. We estimated the proportion of syphilis tests
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that were carried out concurrently with an HIV viral
load test, defined as the same date of specimen collec-
tion or the same date of specimen testing, plus or minus
three days. We compared proportions between MSM,
other males, and females, and over calendar years, using
logistic regression within a generalized estimating equa-
tions (GEE) framework to account for repeated tests per
person.
Next, we calculated annual rates of syphilis testing, de-
fined as the proportion that underwent testing at least once
in a calendar year while under observation in the cohort.
Participants were considered under observation starting at
the year they enrolled in the OCS, or the year 2000, which-
ever was later. They remained under observation for each
subsequent year until their last year of follow-up (i.e., year
of death, loss-to-follow-up, or 2009 for those still under ac-
tive follow-up as of December 31, 2009). We report pro-
portions with 95% confidence intervals (CI).
To assess predictors of testing, we estimated the ratio
of prevalence proportions rather than odds ratios be-
cause the odds ratio can greatly overestimate the ratio of
proportions for a common outcome. We used PROC
GENMOD and Poisson regression using GEE with an
auto-regressive correlation structure. This approach ac-
counts for repeated measures by adjusting standard er-
rors for the actual number of participants and it is also
recommended for calculation of ratios of proportions or
prevalence ratios [15]. For participants who died, we
used an offset to censor their observation at the date of
death, such that they only contributed a fraction of a
person-year during the year of death. Participants who
entered or exited the study in a calendar year due to
consent or loss-to-follow-up contributed a full person-
year because we assumed that provincial in- or out-
migration would have been trivial, and our record linkage
with the PHOL ensures that we would have detected any
testing conducted in Ontario in that year.
We analysed patterns of repeat syphilis testing in the
subset of patients with at least two years of follow-up,
but stratified our analysis by past syphilis test result to
distinguish screening for new infection from follow-up
testing after syphilis diagnosis and treatment. First, we
calculated inter-test intervals among patients whose pre-
vious test(s) was/were non-reactive or who had only
non-acute reactive tests for a period of at least two years;
tests for differences in inter-test intervals were carried
out using linear regression with GEE to account for re-
peated measures person among those who tested three
or more times. Second, we examined patterns of repeat
testing among cases who had their first reactive test in
2006–09, and evaluated follow-up testing in line with
clinical guidelines that recommend repeat syphilis test-
ing of newly-identified cases at (possibly 1), 3, 6, 12, and
24 months following treatment [1,11].
Finally, we used descriptive statistics and 95%CI to es-
timate the period and annual prevalence of a diagnosis
of syphilis, stratified by patient sex and MSM status. In
all prevalence estimates, untested participants remained
in the denominator because all had the potential to have
been screened for and diagnosed with syphilis. Our ap-
proach is analogous to population-based rates of report-
able STI incidence in public health surveillance, which
include the total population in the region in the denom-
inator, regardless of their testing status.We defined
period prevalence of past or current syphilis as the pro-
portion that underwent testing and had at least one re-
active test result over the 2000–09 period; this
approximates lifetime prevalence. We defined annual
prevalence of a diagnosis of past or current syphilis as
the proportion of participants under observation in a
given calendar year who had at least one reactive test re-
sult in that year; for those who had reactive and non-
reactive results in a single year, we classified them as a
prevalent case. We then calculated the annual preva-
lence of a diagnosis of acute syphilis, defined as the pro-
portion of participants who underwent testing and had
at least one acute reactive test in that year. We also
conducted a test-based analysis to compare reactivity
rates by requesting institution type; we used a propor-
tional odds model with GEE for the ordinal response
categories of non-reactive, reactive non-acute, and acute.
Results
On average, participants were male (86%), aged 44 years,
and reported White race (67%). The median year of HIV
diagnosis was 1995 (IQR 1990–2001) (Table 1). At enrol-
ment, the mean CD4 cell count was 455 cells/mm3 (SD 266)
and the median viral load was 1.4 log10 copies/mL.
Syphilis testing
A total of 7,313 syphilis tests were linked to the 4,232
participants, with the majority (81.5%, 3,451/4,232) hav-
ing undergone testing for syphilis at least once in the
2000–09 period. This proportion was highest for MSM
(83.4%, 2,422/2,903) but only slightly more so than
among women (78.3%, 476/608) and non-MSM males
(74.6%, 461/618). Among the 3,451 testers, the median
number of tests was 2 (IQR 1–4).
The majority of tests (85.6%, 6,261/7,313) were or-
dered by the HIV clinic at which the participant had en-
rolled in the OCS. Tests were less commonly ordered by
sexual health clinics (5.0%, 369/7,313 tests) and other
health care providers, e.g., non-HIV specialist family
physicians (9.3%, 683/7,313 tests). MSM testers were
more likely to have undergone testing at sexual health
clinics (11.1%) compared to non-MSM males (5.8%) or
females (4.5%) (chi-squared test, p=.0001).
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Overall, 77.2% (5,646/7,313) of syphilis tests were or-
dered concurrrently with an HIV viral load. This propor-
tion did not vary appreciably between MSM, other
males, and females (data not shown). However, there
was a temporal trend such that the proportion increased
from 44.4% in 2000 to 79.1% in 2009 (p<0.0001).
Annual proportion tested
The annual proportion tested rose from 2.7% (95%CI
1.9, 3.5) in 2000 to a peak of 54.6% (95%CI 52.9, 56.3) in
2009, with most of the increase occurring in the first half
of the decade and minimal changes occurring after 2005
(Figure 1, Table 2). The rise in testing was observed
among all participants. In virtually every calendar year,
testing was most common among MSM. By 2009, the
proportion testing annually was 57.2% (95%CI 55.2,
59.2) among MSM, 49.1% (95%CI 44.7, 53.5) among fe-
males, and 45.7% (95%CI 41.0, 50.3) among non-MSM
males.
Testing was most common among people in their
twenties (Table 2); analysis of age as a continuous vari-
able demonstrated little variation in testing rates among
those aged 30 or older. Testing was more common
among participants who had enrolled in the OCS at pri-
mary care clinics, relative to tertiary, hospital-based HIV
outpatient clinics. Syphilis testing was most likely for
those who were diagnosed with HIV in the same or the
preceding year, for those who had not yet initiated anti-
retroviral therapy, and for those who had undergone
routine HIV laboratory testing at least twice in that year.
Finally, we observed that participants who were tested
for syphilis in one year were approximately twice as
likely to test in the subsequent year, and more so if they
had a reactive test in the preceding year.
We repeated the analysis in a subsample restricted to
MSM, and observed no substantial differences in the
correlates of annual testing (data not shown). We also
repeated the analysis excluding syphilis testing done at
such times may reflect a battery of baseline testing for
HIV patients rather than routine syphilis testing done as
part of ongoing HIV care, and observed little change to
the estimated proportions of annual testing (data not
shown).
Frequency of syphilis testing
Among patients who were tested for syphilis at least
once and were followed for at least two years, 74.6%
(671/900), 62.6% (119/190) and 66.9% (107/160) were
tested two or more times among MSM, other males, and
women, respectively. Among repeat testers who had pre-
viously tested negative or had non-acute reactive results
for a period of at least two years, the median inter-test
interval was 6.0 months (IQR 3.1-11.0). This interval
was shortest among MSM (median 5.5, IQR 3.0-10.1)
compared to other males (median 10.4, IQR 6.2-13.4)
and women (median 11.2, IQR 5.6-14.0); however, the
differences were not statistically significant, nor was
there evidence of a temporal trend (data not shown).
Follow-up testing after syphilis diagnosis and treat-
ment is recommended by clinical guidelines; [1,11]
therefore we examined patterns of repeat testing in a
subset of 199 newly-identified cases who had their first
reactive test in 2006–09. Including only cases who had
sufficient follow-up in the denominator, we observed re-
peat syphilis testing for 20% (40/199) in the subsequent
1–31 days, 39% (75/193) in the subsequent 32–93 days,
43% (74/172) in the subsequent 94–183 days, 56% (66/
119) in the subsequent 184–365 days, and 55% (38/69)
in the subsequent 366–731 days following the first react-
ive result.
Table 1 Characteristics of 4,232 HIV-positive participants









Other risk 146 3.4%












Any HIV antiretroviral medication during follow-up 3739 88.3%
Mean age at baseline* (SD) 43.5 (9.6)
Median year of HIV diagnosis (IQR) 1995 (1990–2001)
Median # months of prospective follow-up (IQR) 22 (13–89)
Mean CD4 cell count/mm3 at baseline* (SD) 455 (266)
Median log10 viral load at baseline* (IQR) 1.4 (1.4-3.7)
MSM, men who have sex with men. IDU, injection drug user. SD, standard
deviation. IQR, interquartile range.
* Baseline = later of January 1, 2000 or enrolment date.
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Prevalence of diagnosed syphilis
Among participants under observation in 2009, 21.0%
(95%CI 19.4, 22.7) of MSM underwent syphilis testing
and had at least one reactive test in 2000–09. The corre-
sponding period prevalence estimates for a diagnosis of
past or current syphilis were 5.3% (95%CI 3.3, 7.4) for
non-MSM males, and 2.6% (95%CI 1.2, 4.0) for females.
We reviewed medical chart data for information on
syphilis stage for the 228 participants who had at least
one acute syphilis test. For the majority (57%, 130), there
was insufficient information to stage. Among the
remaining 98 cases, 87% were diagnosed with infectious
syphilis (primary, secondary, early latent); 10% were di-
agnosed with neurosyphilis, 2% with late latent syphilis
or latent syphilis of unknown duration; and 1% were di-
agnosed with ocular syphilis.
In each calendar year from 2000 to 2009, we calculated
the annual prevalence of a diagnosis of syphilis (Table 3).
The predominant burden of reactive tests, both acute
and non-acute, was among MSM and this increased over
the decade. Conversely, the proportion with reactive re-
sults was far less among non-MSM males or females,
and virtually no acute results were detected in those pa-
tient populations.
Finally, we compared the test-based reactivity rates
according to the type of requesting institution. There
was an association that approached statistical signifi-
cance for syphilis tests ordered at sexual health clinics to
be reactive (35.7%, 132/369) or acute (8.9%, 33/369),
compared to tests ordered by other types of health care
providers (reactive: 25.6%, 1779/6944; acute: 4.3%, 300/
6944; p=0.07 proportional odds regression with GEE).
Discussion
We analysed data from persons in HIV care in Ontario,
Canada in 2000–09 and observed that the annual pro-
portion tested for syphilis rose from 2.7% in 2000 to a
peak of 54.6% in 2009, with most of the increase occur-
ring in the first half of the decade and minimal changes
occurring after 2005. The observed rise in testing is en-
couraging, yet rates still remain far below international
guidelines for screening frequency. The predominant
burden of reactive tests was among MSM and this in-
creased substantially over the decade.
Testing was most common among MSM, people
aged <30 years, those who had tested in the preceding
year, or those with more HIV lab tests in that year. We
consider the latter variable to be a proxy measure of
clinic visit encounters, such that more HIV care visits
provided had more opportunities for syphilis test or-
ders. Similarly, the main predictors of chlamydia and
gonorrhea testing were younger age and more frequent
visits per year among HIV-positive men in care at a
Baltimore HIV clinic [16]. An important correlate of
annual syphilis testing was having been tested in the
preceding year, suggesting that those who test are
likely to test again. Certainly, clinical guidelines advise
that persons diagnosed with syphilis undergo follow-
up testing at 3, 6, 12 and 24 months [1].
Most syphilis tests were ordered by patients’ HIV care
providers and many were ordered concurrently with HIV
viral load testing, suggesting that HIV clinics are a natural
target for further improvements in syphilis screening.
Health care providers are important prompters of syphilis
testing and many MSM already have a practice of routine
Figure 1 Annual proportion tested for syphilis among HIV-positive participants in the OHTN Cohort Study, by MSM status.
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Table 2 Annual proportion tested for syphilis among HIV-positive participants in the OHTN Cohort Study, 2000-2009















Each additional calendar year (a)
2003 cf 2002 1.59 (1.54, 1.69) 1.53 (1.48, 1.58)
2005 cf 2004 1.39 (1.36, 1.42) 1.32 (1.30, 1.35)
2009 cf 2008 1.05 (1.03, 1.08) 0.98 (0.96, 1.01)
STI risk status
MSM 12,912 31.7 1.39 (1.27, 1.53) 1.20 (1.11, 1.30)
Non-MSM males 2,877 22.6 Referent Referent
Females 2,642 26.2 1.17 (1.03, 1.32) 1.03 (0.93, 1.14)
Unknown 277 47.3
Region
Toronto 10,014 31.7 1.19 (1.11, 1.27) 0.83 (0.78, 0.88)
Ottawa 2,527 26.9 0.89 (0.80, 0.99) 0.70 (0.64, 0.77)
Other 6,167 27.8 Referent Referent
Age (b)
<30 years 576 41.8 Referent Referent
30+ years 18,132 29.4 0.72 (0.64, 0.81) 0.89 (0.81, 0.97)
Race/ethnicity
White 13,322 28.6 Referent
Black/African 1,463 28.9 1.01 (0.90, 1.13)
Aboriginal 1,092 32.6 1.13 (1.00, 1.27)
Other 2,363 33.4 1.17 (1.08, 1.27)
Unknown 468 42.5
Nature of care provided at OCS clinic
Primary 4,242 44.5 1.74 (1.64, 1.84) 1.34 (1.27, 1.41)
Tertiary 14,466 25.5 Referent Referent
Diagnosed with HIV in current or preceeding year (b)
No 18,330 29.1 Referent Referent
Yes 378 63.5 1.88 (1.73, 2.04) 1.29 (1.19, 1.41)
Syphilis testing in previous year (b)
Not tested 13,995 18.3 Referent Referent
Non-reactive 3,755 62.0 4.90 (4.69, 5.12) 1.75 (1.66, 1.84)
Reactive 888 73.6 5.45 (5.18, 5.73) 2.01 (1.89, 2.15)
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testing. In a recent online survey in Toronto and Ottawa,
the most commonly mentioned reason for syphilis testing
among HIV-positive MSM was “it is part of my regular
testing pattern” (54%), followed by “my health care pro-
vider suggested it” (27%) (Frank McGee, AIDS Bureau,
Ontario Ministry of Health and Long Term Care, personal
communication July 18, 2012).
Our results suggest that the lifetime prevalence of syph-
ilis is at least 1 in 5 among HIV-positive MSM in Ontario,
and that 3.8% had evidence of acute syphilis infection in
2009, as indicated by RPR titres of 1:16 or higher. Our
findings are consistent with clinic-based studies of HIV-
positive persons conducted elsewhere, for which occur-
rence of new syphilis infection is typically 3-5%, with the
vast majority among MSM [17-20]. The increased propor-
tion of acute syphilis test results imply a substantial and
growing burden for clinical management and treatment.
In preliminary analyses among MSM in our cohort, we es-
timated that the incidence of the first syphilis diagnosis
was 4.0 per 100 person-years (95%CI 3.0, 5.2), and the rate
of re-diagnosis based on a four-fold rise in RPR titre was
even higher at 4.8 per 100 person-years (95% 3.7, 5.5) [21].
Our team is currently conducting an in-depth analysis of
risk factors for incident syphilis and re-diagnoses which
will be the subject of a future paper.
Study limitations include our use of a non-random sam-
ple. Participating clinics serve over three-quarters of HIV
patients undergoing viral load testing in the province [12].
Nevertheless, compared to Ontario surveillance data, [22]
participants were more likely to be MSM or MSM-IDU
but less likely to have been infected via heterosexual activ-
ity. We were unable to determine whether syphilis testing
appropriately reached those at greatest risk of syphilis be-
cause sexual behaviour was unmeasured during the period
of study. It is unknown whether testing was routine, was
prompted by signs or symptoms, sexual exposures, con-
tact tracing, or greater awareness of syphilis outbreak re-
ports. The prevalence analysis was susceptible to selection
bias because only participants who underwent testing
could be included in the numerator. Therefore, prevalence
was underestimated because true cases of syphilis would
have been undetected for asymptomatic, unscreened
cases. Finally, prevalent cases include both recent acquisi-
tions and past syphilis infections.
Conclusions
The rise in testing in Ontario in the first half of the dec-
ade follows closely the surveillance reports of new syph-
ilis outbreaks, with the vast majority of cases among
MSM, many of whom were co-infected with HIV; inci-
dence of reported syphilis rose from 0.4 per 100,000 in
2000 to 4.0 per 100,000 in 2004, followed by a drop to
2.9 per 100,000 in 2005, and then a continued rise to a
peak of 6.0 per 100,000 in 2009 [1-5]. However, since
2005 the annual testing coverage plateaued in the face of
an ever-increasing burden of infection, and was still con-
siderably lower than what would be desirable based on
STI guidelines. There is an urgent need for novel inter-
ventions to boost testing. Similar suboptimal testing has
been observed for other pathogens among HIV patients.
In an HIV clinic with a high degree of awareness of STI
epidemics in Baltimore, Maryland, the introduction of
U.S. CDC guidelines for chlamydia and gonorrhea test-
ing resulted in only a moderate increase in testing for
these pathogens from 12% to 33% tested per year
[16,23]. In general, a Cochrane systematic review deter-
mined that the distribution of printed educational mate-
rials, including clinical guidelines, generally produced
meager benefits in the health care process [24]. Al-
though guidelines serve an important purpose in
Table 2 Annual proportion tested for syphilis among HIV-positive participants in the OHTN Cohort Study, 2000-2009
(Continued)
Test result undetermined (c) 70 35.7
Initiated HIV antiretoviral treatment (b)
Yes 17,620 29.2 0.75 (0.68, 0.83) 0.92 (0.86, 0.99)
No 1,088 38.6 Referent Referent
Number of routine HIV tests in year (b, d)
None 451 4.2 0.18 (0.11, 0.29) 0.23 (0.14, 0.40)
One 1186 23.4 Referent Referent
Two or more 17071 30.9 1.32 (1.20, 1.45) 1.27 (1.16, 1.40)
Each observation represents a single calendar year of active follow-up. We calculated ratios of proportions using Poisson regression within a generalized
estimating equation framework to account for repeated observations. The within-subject correlation coefficient was 0.40 in an intercept-only model. The adjusted
model included all covariates shown except ethnicity.
(a) There were statistically significant quadratic effects of calendar year. Beta coefficients for the linear and quadratic terms were 1.89 (95%CI 1.79, 2.01) and 0.966
(95%CI 0.962, 0.971) in the unadjusted model, and 1.84 (95%CI 1.74, 1.94) and 0.964 (0.960, 0.969) in the adjusted model, respectively.
(b) Time updated each calendar year.
(c) Reasons for unavailable test results in the preceding year included that the specimens were not tested or results were pending.
(d) The number of routine HIV tests in the year was defined as the maximum of the total number of HIV viral load or the total number of CD4 cell count tests in a
calendar year, whichever was greater. It is a proxy measure of the frequency of contact with HIV care.
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clarifying best practice and reach a wide audience at lit-
tle cost, they are insufficient to produce maximal
uptake.
Operational interventions may be necessary to in-
crease syphilis testing rates. For example, standing or-
ders for pneumococcal vaccine are more effective at




Not tested Non-reactive Reactive Reactive &
acute (a)
N % N % N % N %
MSM
2000 1139 1108 97.3 19 1.7 6 0.5 1 0.1
2001 1076 1019 94.7 35 3.3 4 0.4 1 0.1
2002 1093 1006 92.0 67 6.1 12 1.1 5 0.5
2003 1050 927 88.3 83 7.9 36 3.4 15 1.4
2004 1114 899 80.7 162 14.5 47 4.2 17 1.5
2005 1101 708 64.3 330 30.0 61 5.5 15 1.4
2006 1066 576 54.0 384 36.0 100 9.4 12 1.1
2007 1071 575 53.7 392 36.6 103 9.6 7 0.7
2008 1893 1007 53.2 631 33.3 246 13.0 47 2.5
2009 2309 988 42.8 918 39.8 400 17.3 88 3.8
P-value for time trend P < 0.0001 P < 0.0001
Non-MSM Males
2000 254 247 97.2 5 2.0 1 0.4 0 0
2001 245 226 92.2 14 5.7 2 0.8 0 0
2002 253 239 94.5 11 4.3 3 1.2 1 0.4
2003 246 231 93.9 11 4.5 4 1.6 1 0.4
2004 266 238 89.5 28 10.5 0 0 0 0
2005 262 192 73.3 67 25.6 3 1.1 0 0
2006 255 170 66.7 75 29.4 10 3.9 1 0.4
2007 259 165 63.7 84 32.4 10 3.9 0 0
2008 388 274 70.6 102 26.3 12 3.1 0 0
2009 449 244 54.3 192 42.8 11 2.4 0 0
P-value for time trend P = 0.0002 P = 0.4443
Females
2000 197 191 97.0 5 2.5 0 0 0 0
2001 190 177 93.2 10 5.3 0 0 0 0
2002 208 189 90.9 19 9.1 0 0 0 0
2003 201 189 94.0 12 6.0 0 0 0 0
2004 226 200 88.5 26 11.5 0 0 0 0
2005 225 166 73.8 59 26.2 0 0 0 0
2006 233 142 60.9 89 38.2 1 0.4 0 0
2007 238 149 62.6 88 37.0 1 0.4 0 0
2008 425 293 68.9 125 29.4 7 1.6 0 0
2009 499 254 50.9 234 46.9 11 2.2 0 0
P-value for time trend P < 0.0001 n/a
Percentages shown are row percents. For participants who underwent testing more than once in a single calendar year and had both reactive and non-reactive
results, we classified their results as reactive. P-values for calendar year time trends were calculated using logistic regression with GEE.
(a) Acute reactive results were defined as a reactive trepomenal test and RPR titre greater than or equal to 1:16.
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increasing rates of vaccination compared to usual prac-
tice, even more so than computerized reminders [25].
There is a growing body of research which suggests that
clinic-based interventions can be effective in improving
syphilis screening coverage, frequency, and case detec-
tion among HIV-positive MSM [26-29]. Even for studies
conducted in specialist HIV clinics, where physician
knowledge of sexual health and STI issues was presum-
ably high, the interventions resulted in improvements,
suggesting potential benefit even for STI-experienced
providers, and even greater potential for settings with
low or infrequent STI screening [28]. We recommend
that future efforts to improve timely detection and treat-
ment of syphilis in this population include systematic
and operational changes to health care practice, such as
clinic-based interventions.
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